WS #13405

From 500 msgs · 6 key-dev

Novo Nordisk raised its 2026 outlook on strong GLP-1 sales, but shares fell on a flat outlook and a DKK 6.3B impairment, highlighting competitive pressure from Eli Lilly.

Novo Nordisk guidance raise

Novo Nordisk raised its 2026 outlook on strong GLP-1 sales, but shares fell on a flat outlook and a DKK 6.3B impairment, highlighting competitive pressure from Eli Lilly.

Full world state #13405 →